Twice-daily to once-daily lopinavir/ritonavir pharmacokinetics-pharmacodynamics in pediatric patients

被引：0
|
作者：
Foissac, F. [1 ,2 ]
Blanche, S. [1 ]
Hirt, D. [1 ,2 ]
Treluyer, J. M. [1 ,2 ,3 ]
Urien, S. [1 ,2 ]
机构：
[1] Univ Paris 05, Unite Rech Clin, Paris Ctr, EA 3620, Paris, France
[2] INSERM Necker Cochin, CIC 0901, Paris, France
[3] Hop St Vincent de Paul, AP HP, Pharmacol Lab, Paris, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [1] 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
    Johnson, M
    Grinsztejn, B
    Rodriguez, C
    Coco, J
    DeJesus, E
    Lazzarin, A
    Lichtenstein, K
    Wirtz, V
    Righmire, A
    Odeshoo, L
    McLaren, C
    AIDS, 2006, 20 (05) : 711 - 718
  • [2] Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study
    Kreutz, R.
    Persson, P. B.
    Kubitza, D.
    Thelen, K.
    Heitmeier, S.
    Schwers, S.
    Becka, M.
    Hemmrich, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (10) : 2017 - 2028
  • [3] Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
    la Porte, CJL
    Schippers, EF
    van der Ende, ME
    Koopmans, PP
    Blok, WL
    Kauffmann, RH
    Kroon, FP
    Burger, DM
    AIDS, 2005, 19 (10) : 1105 - 1107
  • [4] A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
    Johnson, Margaret A.
    Gathe, Joseph C., Jr.
    Podzamczer, Daniel
    Molina, Jean-Michel
    Naylor, Christian T.
    Chiu, Yi-Lin
    King, Martin S.
    Podsadecki, Thomas J.
    Hanna, George J.
    Brun, Scott C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (02) : 153 - 160
  • [5] Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatmentexperienced patients
    Lathouwers, Erkki
    De la Rosa, Guy
    Van de Casteele, Tom
    Baeten, Benny
    Tomaka, Frank
    De Meyer, Sandra
    Picchio, Gaston
    ANTIVIRAL THERAPY, 2013, 18 (03) : 289 - 300
  • [6] Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naive HIV-Infected Patients
    Rizk, Matthew L.
    Hang, Yaming
    Luo, Wen-Lin
    Su, Jing
    Zhao, Jing
    Campbell, Havilland
    Nguyen, Bach-Yen T.
    Sklar, Peter
    Eron, Joseph J., Jr.
    Wenning, Larissa
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3101 - 3106
  • [7] Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
    Isaac, A
    Taylor, S
    Cane, P
    Smit, E
    Gihbons, SE
    White, DJ
    Drake, SM
    Khoo, S
    Back, DJ
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 498 - 502
  • [8] Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Boffito, M
    Dickinson, L
    Hill, A
    Back, D
    Moyle, G
    Nelson, M
    Higgs, C
    Fletcher, C
    Mandalia, S
    Gazzard, B
    Pozniak, A
    ANTIVIRAL THERAPY, 2004, 9 (03) : 423 - 429
  • [9] Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
    Thompson, M
    DeJesus, E
    Richmond, G
    Wheeler, D
    Flaherty, J
    Piliero, P
    True, A
    Chiu, YY
    Zhang, Y
    McFalls, E
    Miralles, GD
    Patel, IH
    AIDS, 2006, 20 (03) : 397 - 404
  • [10] Lopinavir/ritonavir pharmacokinetic profile: Impact of sex and other covariates following a change from twice-daily to once-daily therapy
    Ofotokun, Ighovwerha
    Chuck, Susan K.
    Binongo, Jose N.
    Palau, Mauricio
    Lennox, Jeffrey L.
    Acosta, Edward P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (08): : 970 - 977
12345